100% found this document useful (4 votes)
15K views3 pages

Drug Study - Levetiracetam

1. The document provides information about the drug Levetiracetam (Keppra), including its dosage, mechanism of action, indications, contraindications, adverse effects, and nursing responsibilities. 2. Levetiracetam is used to treat seizures by inhibiting neuronal firing and spread of seizure activity in the brain. It is taken once daily at bedtime. 3. Common adverse effects include headache, dizziness, somnolence, and irritability. Nurses should monitor patients for these effects and educate them about risks of abruptly stopping the drug.

Uploaded by

Cath Bril
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
100% found this document useful (4 votes)
15K views3 pages

Drug Study - Levetiracetam

1. The document provides information about the drug Levetiracetam (Keppra), including its dosage, mechanism of action, indications, contraindications, adverse effects, and nursing responsibilities. 2. Levetiracetam is used to treat seizures by inhibiting neuronal firing and spread of seizure activity in the brain. It is taken once daily at bedtime. 3. Common adverse effects include headache, dizziness, somnolence, and irritability. Nurses should monitor patients for these effects and educate them about risks of abruptly stopping the drug.

Uploaded by

Cath Bril
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd

Name of Student: Catherine B.

Jordan Section and Group Number: 3E - Group 2


Name of CI: Sarah Jane M. Rosales, RN MAN Area of Exposure: NEURO Ward

DRUG STUDY – Levetiracetam


Dosage,
Mechanism of
Name of Drug Frequency, Indication Contraindications & Cautions Adverse Effects Nursing Responsibilities
Action
Route
Generic Name: Dosage: May act by inhibiting Levetiracetam is used  Contraindicated in patients  CNS: Asthenia, headache, Nursing Considerations:
Levetiracetam 500mg/tab, 1 tab simultaneous neuronal with hypersensitive to the drug. amnesia, anxiety, ataxia,  Use drug only with other anticonvulsants;
firing that leads to other medications to depression, dizziness, hostility, it is not recommended for monotherapy.
Brand Name: Frequency: seizure activity. It treat seizures The following conditions are nervousness, paresthesia, pain,  Seizures can occur if drug is stopped
Keppra ODHS (at inhibits the spread of (epilepsy). It belongs to contraindicated with this drug: vertigo, hypersomnia, irritability, abruptly. Tapering is recommended.
bedtime) seizure activity in the a class of drugs known  anemia insomnia, confusion, falls,  Monitor patients for signs and symptoms
Classifications: brain. as anticonvulsants.  decreased blood platelets sedation, abnormal gait, of somnolence and fatigue. Somnolence
Therapeutic Class: Route: Levetiracetam may  low levels of white blood cells incoordination. and asthenia occurred most frequently
Anticonvulsants PO decrease the number of  low levels of a type of white blood cell  EENT: diplopia, conjunctivitis, ear within first weeks of treatment.
seizures a person has. called neutrophils pain, rhinitis, sinusitis, nasal  Monitor patient closely for such adverse
Pharmacologic  psychotic disorder congestion, pharyngitis. reactions as dizziness, which may lead to
Class:  suicidal thoughts  GI: anorexia, vomiting, upper falls.
Pyrrolidine  depression abdominal pain, diarrhea,  Discontinue and notify prescriber for
derivatives  hallucinations constipation, gastroenteritis. signs and symptoms of anaphylaxis
 abnormal manner of walking  Hematologic: leukopenia, (hypotension, hives, rash, and respiratory
 loss of muscle coordination chronic neutropenia. distress) and of angioedema (swelling of
kidney disease (stage 2 mild, stage 3A  Musculoskeletal: neck pain, joint face, lips, mouth, eyes, tongue, throat, and
moderate, stage 3B moderate, stage 4 sprain. feet).
severe)  Respiratory: cough  Monitor renal function as acute kidney
 kidney disease with likely reduction in  Skin: contusion injury has been reported.
kidney function  Other: infection, head injury,  Closely monitor for changes in behavior
flulike symptoms. indicating psychosis or worsening of
Allergies: suicidal thoughts or behavior or
Pyrrolidone Analogues depression.

1
Patient and Family Education:
 Tell patient to seek medical attention for
emerging or worsening depression,
suicidal thoughts or behavior, or unusual
changes in mood or behavior and to report
such symptoms as anxiety, agitation,
hostility, mania, and hypomania, which
may be precursors to emerging
suicidality.
 Warn patient to use extra care when
sitting or standing to avoid falling.
 Advise patient to seek immediate medical
attention for signs and symptoms of
anaphylaxis or angioedema.
 Advise patient to call subscriber and not
to stop drug suddenly if adverse reactions
occur.
 Tell the patient to take with other
prescribed seizure drugs.
 Warn the patient that drug may cause
dizziness and somnolence and to avoid
driving, operating heavy machinery, bike
riding, or other hazardous activities until
drug’s effects are known.
 Inform the patient that drug can be taken
with or without food.
 Tell the patient not to chew, crush, or
break tablets.
 Advise the patient no to stop drug
abruptly because seizure activity may
increase.
Source: Nursing Drug Source: Nursing Drug Source: Nursing Drug Source: Nursing Drug Handbook, 2020 Source: Nursing Drug Handbook, 2020 Source: Nursing Drug Handbook, 2020

2
Handbook, 2020 Handbook, 2020 Handbook, 2020 p. 925 p. 925 p. 926
p. 923 p. 924 p. 923

Name of Student: Catherine B. Jordan
Section and Group Number: 3E - Group 2
Name of CI:  Sarah Jane M. Rosales, RN MAN
Area o
Patient and Family Education:
Tell patient to seek medical attention for
emerging  or  worsening  depression,
suicidal thoug
Handbook, 2020 
p. 923
Handbook, 2020 
p. 924
Handbook, 2020 
p. 923
p. 925
p. 925
p. 926
3

You might also like